CENTOGENE NV (CNTG)
NL0014040206 - Common Stock
CENTOGENE NV
NASDAQ:CNTG (4/26/2024, 10:56:56 AM)
0.49
+0.01 (+2.1%)
Company Profile
Centogene NV is a commercial-stage company, which focuses on rare diseases that transform real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies. The company is headquartered in Rostock, Mecklenburg-Vorpommern and currently employs 517 full-time employees. The company went IPO on 2019-11-07. The firm focuses on rare diseases, transforming clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies. The firm's platform includes epidemiological, phenotypic, and genetic data reflecting a global population, as well as a biobank of blood samples from these patients. The firm's pharmaceutical segment provides a variety of services to its pharmaceutical partners, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring. The firm's Clinical Diagnostics segment provides targeted genetic sequencing and diagnostic services to patients through its distribution partners and customers, which are typically physicians, laboratories or hospitals.
Company Info
CENTOGENE NV
Am Strande 7
Rostock MECKLENBURG-VORPOMMERN 18055
P: 4938180113400
CEO: Andrin Oswald
Employees: 517
Website: https://www.centogene.com/
CNTG News
7 days ago - InvestorPlaceToday’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayFriday is here and we're breaking down the biggest pre-market stock movers that traders need to know about this morning!
24 days ago - Centogene NVCENTOGENE Receives Nasdaq Non-Compliance NoticeCAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, April 02, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (“Centogene”, “we”, or the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced that it received a notification letter dated March 27, 2024, from the Nasdaq Stock Market LLC Listing Qualifications Department, indicating that the Company was not in compliance with the minimum bid price requirement set forth in Rule 5450(a)(1) of the Nasdaq Listing Rules since the closing bid price for the Company's common shares listed on Nasdaq was below US$1.00 for 30 consecutive business days (from February 12 through March 26, 2024). Nasdaq Rule 5450(a)(1) requires the shares to maintain a minimum bid price of US$1.00 per share, and Nasdaq Rule 5810(c)(3)(A) provides that failure to meet such a requirement exists when the bid price of the shares is below US$1.00 for a period of 30 consecutive business days.
a month ago - Centogene NVCENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage DisordersLongstanding global partnership provides an efficient and timely diagnosis to patients with Lysosomal Storage Disorders (LSDs) CAMBRIDGE, Mass. and...
2 months ago - Centogene NVCENTOGENE Collaborates on Research Published in Science Showing Immunopathological Landscape of Human Pre-TCRα DeficiencyComplete Pre-TCRα Deficiency Found to be Very Rare, Partial Form More Common Than Expected
CNTG Twits
Here you can normally see the latest stock twits on CNTG, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
